Matthew Chau Hsien Ng

Author

Also Known As

Azad, Nilofer S, M Ng, M. Ng, M.C.H. Ng, Matthew C H Ng, Matthew C. H. Ng, Matthew C.H. Ng, Matthew CH Ng, Matthew Chau Hsien Ng, Matthew NG

132

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

National Cancer Centre Singapore National University Cancer Institute, Singapore National University of Singapore Duke-NUS Medical School Seoul National University Hospital

About

Matthew Chau Hsien Ng is an author at National Cancer Centre Singapore specializing in oncology, radiation oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	594
2	Health Sciences	3	3	188
3	Hepatology	3	3	174
4	Cell Biology	2	2	66
5	Gastroenterology	2	2	60

Matthew Chau Hsien Ng

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS Kei Muro, Eric Van Cutsem, Yukiya Narita, Annals of Oncology	2018	214
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial Daniel V.T. Catenacci, Yoon‐Koo Kang, Haeseong Park, The Lancet Oncology OncologyEsophageal CancerGastrointestinal OncologyPathologyImmune Checkpoint Inhibitor	2020	186
Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial David Tai, Kelvin Siu Hoong Loke, Apoorva Gogna, The Lancet. Gastroenterology & hepatology HepatologyHepatocellular CarcinomaSingle ArmMedicineY90-resin Microspheres	2021	117
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer Kohei Shitara, Tania Fleitas, Hisato Kawakami, ESMO Open	2024	73
Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery Sarah B. Ng, Clarinda Chua, Matthew Chau Hsien Ng, Scientific Reports	2017	61
Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC Aaron C. Tan, A. Seet, Gillianne Lai, Journal of Thoracic Oncology	2020	52
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein Min Thura, Abdul Qader Al-Aidaroos, Abhishek Gupta, Nature Communications	2019	47
A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer Y.-J. Bang, Yoon‐Koo Kang, Matthew Chau Hsien Ng, European Journal of Cancer Esophageal CancerPhase IiAkt Inhibitor IpatasertibGastrointestinal OncologyMedicine	2018	44
A phase II open-label, single-center, nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma: CA 209-678. Wai Meng David Tai, Kelvin Siu Hoong Loke, Apoorva Gogna, Journal of Clinical Oncology Phase Ii Open-labelY90-re FieldPathologyNonrandomized TrialOncology	2020	38
Spatially Resolved Niche and Tumor Microenvironmental Alterations in Gastric Cancer Peritoneal Metastases Joseph J. Zhao, Chin‐Ann Johnny Ong, Supriya Srivastava, Gastroenterology	2024	37

Page 1